Insight Molecular Diagnostics Inc. Common Stock IMDX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$47.84M+4.7% | -$50.22M+17.4% | -$60.78M+4.2% | -$63.42M-9.0% | -$58.21M+4.1% | ||
| $2.34M+6.7% | $2.19M+1.0% | $2.17M+14.0% | $1.9M+15.5% | $1.65M+11.6% | ||
| $2.36M+6.4% | $2.22M+11.1% | $2M+3.7% | $1.93M+6.5% | $1.81M+3.1% | ||
| —— | —— | $49K-88.5% | $427K-87.4% | $3.38M+199% | ||
| —— | —— | —— | $693K+51.0% | $459K+12.0% | ||
| $1.51M-42.8% | $2.65M+1,391% | -$205K+72.0% | -$733K-164% | $1.14M+17.9% | ||
| —— | —— | —— | $569K+22.4% | $465K+5.2% | ||
| $14.59M0.0% | $14.6M-65.1% | $41.84M-0.1% | $41.86M-0.1% | $41.89M0.0% | ||
| -$195K-37.3% | -$142K+51.0% | -$290K-24.5% | -$233K-3.6% | -$225K+22.7% | ||
| —— | —— | -$6.64M-131% | -$2.87M+57.2% | -$6.71M-56.9% | ||
| -$23.98M-8.1% | -$22.18M-0.9% | -$21.99M+4.5% | -$23.02M-1.4% | -$22.7M-9.7% | ||
| $3.49M+9.6% | $3.19M+65.9% | $1.92M+101% | $957K+19.8% | $799K+54.8% | ||
| -$3.49M-9.6% | -$3.19M-66.2% | -$1.92M-101% | -$953K-19.9% | -$795K-55.3% | ||
| —— | —— | —— | —— | $55.16M+112% | ||
| —— | $72K+33.3% | $54K+50.0% | $36K+100% | $18K— | ||
| —— | $2K+33.3% | $1.5K+50.0% | $1K+100% | $500— | ||
| —— | —— | —— | —— | $49.24M+138% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $86K-5.5% | $91K-3.2% | $94K+8.0% | $87K+31.8% | $66K+57.1% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $0-100% | $7K-75.9% | $29K-43.1% | $51K-30.1% | $73K-17.0% | ||
| —— | —— | -$6.64M-131% | -$2.87M+57.2% | -$6.71M-56.9% | ||
| $182K+11.0% | $164K-6.8% | $176K+15.8% | $152K— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$195K-37.3% | -$142K+51.0% | -$290K-24.5% | -$233K-3.6% | -$225K+22.7% | ||
| —— | —— | —— | $569K+22.4% | $465K+5.2% | ||
| —— | —— | —— | —— | $1.86M+35.4% | ||
| $555K+8.8% | $510K+23.2% | $414K+8.9% | $380K— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$195K-37.3% | -$142K+51.0% | -$290K-24.5% | -$233K-3.6% | -$225K+22.7% | ||
| $1.05M-7.8% | $1.14M+205% | $373K-54.1% | $813K-28.2% | $1.13M-36.9% | ||
| —— | —— | —— | —— | —— | ||
| —— | $2K+33.3% | $1.5K+50.0% | $1K+100% | $500— | ||
| $0— | $0— | $0— | $0— | $0— | ||
| -$27.48M-8.3% | -$25.37M-6.1% | -$23.91M+0.3% | -$23.98M-2.0% | -$23.5M-10.8% | ||
| -$27.48M-8.3% | -$25.37M-6.1% | -$23.91M+0.3% | -$23.98M-2.0% | -$23.5M-10.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Insight Molecular Diagnostics Inc. Common Stock generate?
- Insight Molecular Diagnostics Inc. Common Stock (IMDX) generated -$24.0M in operating cash flow over the trailing twelve months.
- What is Insight Molecular Diagnostics Inc. Common Stock's free cash flow?
- After $3.5M of capital expenditures, Insight Molecular Diagnostics Inc. Common Stock's free cash flow was -$27.5M over the trailing twelve months, down 16.9% year over year.
- Where does Insight Molecular Diagnostics Inc. Common Stock's cash flow data come from?
- Every line is extracted from Insight Molecular Diagnostics Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
